Sagimet Biosciences Inc. (SGMT) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$15.82M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$11.71M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$14.33M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$11.93M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$15.82M | (m) | (m) | (m) | (m) | -$11.10M* | (m) | $11.54M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$11.71M | (m) | (m) | (m) | (m) | -$8.61M | (m) | $7.00M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$14.33M | (m) | (m) | (m) | (m) | -$10.18M* | (m) | $9.73M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$11.93M | (m) | (m) | (m) | (m) | -$9.10M* | (m) | $7.25M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$19.86M | (m) | (m) | (m) | (m) | -$14.54M | (m) | $15.34M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$16.90M | (m) | (m) | (m) | (m) | -$19.57M* | (m) | $12.65M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$10.59M | (m) | (m) | (m) | (m) | -$5.63M* | (m) | $6.31M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$8.77M | (m) | (m) | (m) | (m) | -$6.21M | (m) | $5.26M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$7.45M | (m) | $2.00M | (m) | (m) | -$3.88M* | (m) | $4.96M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$7.06M | (m) | (m) | (m) | (m) | -$5.72M* | (m) | $4.68M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$6.76M | (m) | (m) | (m) | (m) | -$7.08M | (m) | $4.49M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$7.69M | (m) | (m) | (m) | (m) | -$6.23M* | (m) | $6.84M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$7.24M | (m) | (m) | (m) | (m) | -$3.00K* | (m) | $6.37M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$56.89M | (m) | (m) | (m) | (m) | -$45.65M | (m) | $39.05M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$54.45M | (m) | (m) | (m) | (m) | -$42.44M | (m) | $38.44M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$30.74M | (m) | $2.00M | (m) | (m) | -$23.77M | (m) | $19.78M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$31.05M | (m) | (m) | (m) | (m) | -$24.49M | (m) | $24.92M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |